-
Je něco špatně v tomto záznamu ?
Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients
Z. Betteridge, S. Tansley, G. Shaddick, H. Chinoy, RG. Cooper, RP. New, JB. Lilleker, J. Vencovsky, L. Chazarain, K. Danko, M. Nagy-Vincze, L. Bodoki, M. Dastmalchi, L. Ekholm, IE. Lundberg, N. McHugh, UKMyonet contributors,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
18474
Versus Arthritis - United Kingdom
MR/N003322/1
Medical Research Council - United Kingdom
- MeSH
- autoprotilátky imunologie MeSH
- dermatomyozitida epidemiologie imunologie MeSH
- dospělí MeSH
- kohortové studie MeSH
- komorbidita MeSH
- lidé středního věku MeSH
- lidé MeSH
- myozitida diagnóza epidemiologie imunologie MeSH
- náchylnost k nemoci imunologie MeSH
- odds ratio MeSH
- polymyozitida epidemiologie imunologie MeSH
- prevalence MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
OBJECTIVES: To determine prevalence and co-existence of myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs) and associated clinical characteristics in a large cohort of idiopathic inflammatory myopathy (IIM) patients. METHODS: Adult patients with confirmed IIM recruited to the EuroMyositis registry (n = 1637) from four centres were investigated for the presence of MSAs/MAAs by radiolabelled-immunoprecipitation, with confirmation of anti-MDA5 and anti-NXP2 by ELISA. Clinical associations for each autoantibody were calculated for 1483 patients with a single or no known autoantibody by global linear regression modelling. RESULTS: MSAs/MAAs were found in 61.5% of patients, with 84.7% of autoantibody positive patients having a sole specificity, and only three cases (0.2%) having more than one MSA. The most frequently detected autoantibody was anti-Jo-1 (18.7%), with a further 21 specificities each found in 0.2-7.9% of patients. Autoantibodies to Mi-2, SAE, TIF1, NXP2, MDA5, PMScl and the non-Jo-1 tRNA-synthetases were strongly associated (p < 0.001) with cutaneous involvement. Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15). Interstitial lung disease was strongly associated with the anti-tRNA synthetases, anti-MDA5, and anti-U1RNP/Sm. Overlap disease was strongly associated with anti-PMScl, anti-Ku, anti-U1RNP/Sm and anti-Ro60. Absence of MSA/MAA was negatively associated with extra-muscular manifestations. CONCLUSIONS: Myositis autoantibodies are present in the majority of patients with IIM and identify distinct clinical subsets. Furthermore, MSAs are nearly always mutually exclusive endorsing their credentials as valuable disease biomarkers.
Department of Internal Medicine University of Debrecen Debrecen Hungary
Department of Mathematics University of Exeter Exeter UK
Department of Pharmacy and Pharmacology University of Bath Bath UK
Institute of Ageing and Chronic Disease University of Liverpool Liverpool UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025801
- 003
- CZ-PrNML
- 005
- 20201222154114.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jaut.2019.04.001 $2 doi
- 035 __
- $a (PubMed)30992170
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Betteridge, Z $u Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
- 245 10
- $a Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients / $c Z. Betteridge, S. Tansley, G. Shaddick, H. Chinoy, RG. Cooper, RP. New, JB. Lilleker, J. Vencovsky, L. Chazarain, K. Danko, M. Nagy-Vincze, L. Bodoki, M. Dastmalchi, L. Ekholm, IE. Lundberg, N. McHugh, UKMyonet contributors,
- 520 9_
- $a OBJECTIVES: To determine prevalence and co-existence of myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs) and associated clinical characteristics in a large cohort of idiopathic inflammatory myopathy (IIM) patients. METHODS: Adult patients with confirmed IIM recruited to the EuroMyositis registry (n = 1637) from four centres were investigated for the presence of MSAs/MAAs by radiolabelled-immunoprecipitation, with confirmation of anti-MDA5 and anti-NXP2 by ELISA. Clinical associations for each autoantibody were calculated for 1483 patients with a single or no known autoantibody by global linear regression modelling. RESULTS: MSAs/MAAs were found in 61.5% of patients, with 84.7% of autoantibody positive patients having a sole specificity, and only three cases (0.2%) having more than one MSA. The most frequently detected autoantibody was anti-Jo-1 (18.7%), with a further 21 specificities each found in 0.2-7.9% of patients. Autoantibodies to Mi-2, SAE, TIF1, NXP2, MDA5, PMScl and the non-Jo-1 tRNA-synthetases were strongly associated (p < 0.001) with cutaneous involvement. Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15). Interstitial lung disease was strongly associated with the anti-tRNA synthetases, anti-MDA5, and anti-U1RNP/Sm. Overlap disease was strongly associated with anti-PMScl, anti-Ku, anti-U1RNP/Sm and anti-Ro60. Absence of MSA/MAA was negatively associated with extra-muscular manifestations. CONCLUSIONS: Myositis autoantibodies are present in the majority of patients with IIM and identify distinct clinical subsets. Furthermore, MSAs are nearly always mutually exclusive endorsing their credentials as valuable disease biomarkers.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a autoprotilátky $x imunologie $7 D001323
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a dermatomyozitida $x epidemiologie $x imunologie $7 D003882
- 650 _2
- $a náchylnost k nemoci $x imunologie $7 D004198
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myozitida $x diagnóza $x epidemiologie $x imunologie $7 D009220
- 650 _2
- $a odds ratio $7 D016017
- 650 _2
- $a polymyozitida $x epidemiologie $x imunologie $7 D017285
- 650 _2
- $a prevalence $7 D015995
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Tansley, S $u Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
- 700 1_
- $a Shaddick, G $u Department of Mathematics, University of Exeter, Exeter, UK.
- 700 1_
- $a Chinoy, H $u Centre for Musculoskeletal Research, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; National Institute of Health Research Manchester Biomedical Research Centre, Manchester University Foundation Trust.UK; Salford Royal NHS Foundation Trust, Manchester, UK.
- 700 1_
- $a Cooper, R G $u Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
- 700 1_
- $a New, R P $u Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
- 700 1_
- $a Lilleker, J B $u Centre for Musculoskeletal Research, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Salford Royal NHS Foundation Trust, Manchester, UK.
- 700 1_
- $a Vencovsky, J $u Institute of Rheumatology and Department of Rheumatology, 1stMedical Faculty, Charles University, Prague, Czech Republic.
- 700 1_
- $a Chazarain, L $u Institute of Rheumatology and Department of Rheumatology, 1stMedical Faculty, Charles University, Prague, Czech Republic.
- 700 1_
- $a Danko, K $u Department of Internal Medicine, University of Debrecen, Debrecen, Hungary.
- 700 1_
- $a Nagy-Vincze, M $u Department of Internal Medicine, University of Debrecen, Debrecen, Hungary.
- 700 1_
- $a Bodoki, L $u Department of Internal Medicine, University of Debrecen, Debrecen, Hungary.
- 700 1_
- $a Dastmalchi, M $u Division of Rheumatology, Department of Medicine, Solna Karolinska Institutet, And Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Ekholm, L $u Division of Rheumatology, Department of Medicine, Solna Karolinska Institutet, And Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Lundberg, I E $u Division of Rheumatology, Department of Medicine, Solna Karolinska Institutet, And Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a McHugh, N $u Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. Electronic address: n.j.mchugh@bath.ac.uk.
- 710 2_
- $a UKMyonet contributors
- 773 0_
- $w MED00002536 $t Journal of autoimmunity $x 1095-9157 $g Roč. 101, č. - (2019), s. 48-55
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30992170 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222154110 $b ABA008
- 999 __
- $a ok $b bmc $g 1599946 $s 1116487
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 101 $c - $d 48-55 $e 20190413 $i 1095-9157 $m Journal of autoimmunity $n J Autoimmun $x MED00002536
- GRA __
- $a 18474 $p Versus Arthritis $2 United Kingdom
- GRA __
- $a MR/N003322/1 $p Medical Research Council $2 United Kingdom
- LZP __
- $a Pubmed-20201125
